Citius Oncology reports promising early data for LYMPHIR combination at ASCO
Share
Citius Oncology (NASDAQ:CTOR) showcased positive early-stage clinical trial results, demonstrating the potential of its targeted immune therapy LYMPHIR to enhance the efficacy of checkpoint inhibitors in treating recurrent or refractory gynecologic cancers.
